LB Pharmaceuticals Names Neuroscience R&D Veteran Robert Lenz to Board
LB Pharmaceuticals has appointed R&D executive Robert Lenz, M.D., Ph.D., with over 20 years of neuroscience drug development experience, to its Board of Directors. Lenz’s leadership roles at Neumora Therapeutics, Amgen and Abbott Laboratories will support the late-stage clinical advancement of LB-102 across multiple neuropsychiatric indications.
1. Appointment Details
LB Pharmaceuticals has appointed Robert Lenz, M.D., Ph.D., to its Board of Directors, bringing over 20 years of leadership in neuroscience drug development. Lenz’s career includes serving as EVP and Head of R&D at Neumora Therapeutics and senior positions at Amgen and Abbott Laboratories, overseeing multiple drug approvals.
2. Impact on LB-102 Program
Lenz’s proven ability to advance therapies through regulatory review is expected to enhance the late-stage clinical progression of LB-102 in schizophrenia, bipolar depression and adjunctive MDD. His focus on balanced efficacy and tolerability profiles complements the company’s strategy to position LB-102 as a differentiated antipsychotic therapy.